Keyphrases
Breast Cancer
54%
Breast Cancer Patients
45%
Human Epidermal Growth Factor Receptor 2 (HER2)
29%
Overall Survival
23%
Early Breast Cancer
22%
Tumor
18%
Metastatic Breast Cancer
16%
Cooperative Group
15%
Trastuzumab
15%
Advanced Breast Cancer
14%
Chemotherapy
14%
Epirubicin
14%
Cyclophosphamide
12%
Adjuvant Chemotherapy
11%
Primary Breast Cancer
11%
Estrogen Receptor-positive
10%
Adjuvant Therapy
10%
Aromatase Inhibitors
9%
Estrogen Receptor-positive Breast Cancer
9%
Breast Cancer Recurrence
9%
Docetaxel
9%
Breast Cancer Risk
9%
Hazard Ratio
8%
Denmark
8%
HER2-positive
8%
Disease-free Survival
8%
Fluorouracil
8%
Estrogen Receptor
8%
Metastasis
7%
Progression-free Survival
7%
PIK3CA mutation
6%
HER2-positive Breast Cancer
6%
Letrozole
6%
Anthracyclines
6%
Breast Cancer Progression
6%
Aberrations
6%
High Risk
6%
Confidence Interval
6%
Fulvestrant
5%
Palbociclib
5%
Electronic Patient-reported Outcome (ePRO)
5%
Fluorescence in Situ Hybridization
5%
Median Progression-free Survival
5%
Methotrexate
5%
Neoadjuvant
5%
Tumor-infiltrating Lymphocytes
5%
Median Overall Survival
5%
HER2-positive Metastatic Breast Cancer
5%
Normal Breast
5%
Primary Tumor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
93%
Neoplasm
27%
Overall Survival
22%
Metastatic Breast Cancer
17%
Chemotherapy
16%
Estrogen Receptor
14%
Cyclophosphamide
13%
Epirubicin
13%
Recurrent Disease
12%
Trastuzumab
12%
Docetaxel
11%
Epidermal Growth Factor Receptor 2
11%
Progression Free Survival
10%
Gamma Urogastrone
10%
Malignant Neoplasm
9%
Fluorouracil
8%
Aromatase Inhibitor
8%
Disease Free Survival
8%
Tamoxifen
6%
Retrospective Study
6%
Anthracycline
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Epidermal Growth Factor Receptor
6%
Fulvestrant
6%
Methotrexate
6%
Palbociclib
5%
Hormone Receptor
5%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
29%
Estrogen Receptor
18%
Overall Survival
13%
Metastatic Breast Cancer
13%
Adjuvant Chemotherapy
11%
Recurrent Disease
11%
Epidermal Growth Factor Receptor 2
11%
Aromatase Inhibitor
10%
Gamma Urogastrone
10%
Adjuvant Therapy
10%
Hormone Therapy
9%
Trastuzumab
8%
Tamoxifen
8%
Malignant Neoplasm
7%
Patient-Reported Outcome
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
7%
Symptom
6%
Estrogen Receptor Positive Breast Cancer
6%
Metastatic Carcinoma
6%
Letrozole
6%
Postmenopause
6%
Disease
6%
Breast Carcinoma
5%
Recurrence Risk
5%
Tumor Infiltrating Lymphocyte
5%
Fulvestrant
5%
Hormone Receptor
5%
